Neurocrine Biosciences stock: Q3 results set for November 2

Neurocrine Biosciences has scheduled its third-quarter 2026 results release for November 2, 2026. The company said the financial update will be published at 4:00 p.m. Eastern Time, followed by a conference call at 4:30 p.m. Eastern Time. The schedule was announced on October 12, according to the Financial Times company announcement, which reproduces the company release.

Results will test commercial momentum

The release does not provide third-quarter financial figures or guidance. It says Neurocrine Biosciences is focused on treatments for under-addressed neurological, psychiatric, endocrine and immunological disorders, with marketed products spanning tardive dyskinesia, Huntington's disease, classic congenital adrenal hyperplasia and hyperphagia associated with Prader-Willi syndrome.

For investors, the forthcoming report should provide a fresh read on demand, product execution and the company's development pipeline. The scheduled call may also clarify how management views the balance between commercial investment and future growth, although no new outlook was included in the scheduling announcement.

Share price snapshot

Lang & Schwarz recorded Neurocrine Biosciences at EUR 131.00 on October 29, 2026, at 22:59:30 Berlin time. The snapshot showed a bid of EUR 130.75 and an ask of EUR 131.25. The quote is dated and is presented without a daily percentage comparison because no verified Xetra reference is included here.

Investors can follow the real-time quote of Neurocrine Biosciences stock for later market updates.

In the broader market, US healthcare shares remain part of the risk backdrop tracked through the S&P 500 market topic.

Further company developments are available in more news and analyses on Neurocrine Biosciences stock.